November 7, 2016
Press Release
The Research Foundation for Microbial Diseases of Osaka University
Mitsubishi Tanabe Pharma Corporation
Basic Agreement on the Establishment of a Joint Venture
The Research Foundation for Microbial Diseases of Osaka University ("BIKENFoundation") and Mitsubishi Tanabe Pharma Corporation ("Mitsubishi TanabePharma") have reached a basic agreement to establish the joint venture "BIKEN
Corporation" on the basis of BIKEN Foundation's vaccine manufacturing business.
1. Reasons for Establishing a Joint Venture
The BIKEN Foundation is a specialized manufacturer that has engaged in vaccine
manufacture and sale for over 80 years. Under its founding mission to "protecting
precious lives around the world through excellent vaccines." the BIKEN Foundation has
devoted itself to research and development of a wide range of vaccines for preventing
infectious diseases and has produced many of Japan's first vaccines. Currently, theBIKEN Foundation supplies the largest amount of vaccines to the Japanese market.
However, in recent years, due to the outbreak of various infectious diseases, supply
statuses of vaccines, and other circumstances, the Foundation is expected to further
increase its vaccine supply.
Meanwhile, Mitsubishi Tanabe Pharma has cooperated with BIKEN Foundationfor over 50 years as a distributor of BIKEN Foundation-manufactured vaccines. In theyears to come, Mitsubishi Tanabe Pharma will establish BIKEN Corporation and help
enhance its production system, thereby ensuring a consistent supply of competitive andhigh-quality vaccines in both Japanese and overseas markets.
The joint venture that the BIKEN Foundation and Mitsubishi Tanabe Pharma plan
to establish will combine Mitsubishi Tanabe Pharma's pharmaceutical production
systems, management methods, and other strengths with the BIKEN Foundation'svaccine manufacturing technologies, thereby accelerating enhancement of BIKEN'smanufacturing base. By doing so, the joint venture is hoped to contribute to an evenmore steady supply of vaccines.
BIKEN Corporation and the BIKEN Foundation will combine their strengths as avaccine specialist group called the "BIKEN Group" and work for better public healthboth in Japan and the entire world.

12. Outline of the Joint Venture
The BIKEN Foundation and Mitsubishi Tanabe Pharma have agreed on thefollowing matters. The parties will also decide on other specific matters throughdiscussions.
(1) Name: BIKEN Corporation(2) Location: Kanonji City, Kagawa Prefecture, Japan(3) Business: Vaccine manufacture(4) Start date of operation: Scheduled on September 1, 2017(5) Capital: To be decided(6) Capital contribution ratios: BIKEN Foundation

66.6%

Mitsubishi Tanabe Pharma 33.4%(7) Representative: To be decided (To be sent from BIKEN Foundation)(8) Officers: Directors (four from BIKEN Foundation, and two from Mitsubishi Tanabe
Pharma)Corporate auditors (one full-time auditor from BIKEN Foundation, and one
part-time auditor from Mitsubishi Tanabe Pharma)(9) Employees: Approximately 500 production operators, to be loaned mainly fromBIKEN Foundation
Employees engaged in joint-venture business, to be loaned from
Mitsubishi Tanabe Pharma
3. Parties to the Basic Agreement(1) The Research Foundation for Microbial Diseases of Osaka University
Name

The Research Foundation for Microbial Diseases ofOsaka University

Location

Osaka University, 3-1 Yamadaoka, Suita city,
Osaka 565-0871, Japan

Representative

Koichi Yamanishi, Director General

Business activities

Research on microbial diseases, manufacture andsale of vaccines, etc., aid to academic research,clinical trials

Basic fund

JPY 500,050,000

Date of foundationJune 6, 1934

Number of employees

823 (end of September 2016)

Sales

JPY 36.3 billion (FY2015)2(2) Mitsubishi Tanabe Pharma Corporation
Name

Mitsubishi Tanabe Pharma Corporation

Location

3-2-10 Dosho-machi, Chuo-ku, Osaka city 541-8505,
Japan

Representative

Masayuki Mitsuka,
President & Representative Director

Business activities

Manufacture and sale of pharmaceuticals, centeredon ethical drugs

CapitalJPY 50 billion

Date founded

December 15, 1933

Number of employees

7,373 (end of September 2016)

Sales

JPY 431,7 billion (FY2015)

4. Plan for the Immediate Future
The parties will continue studies and discussions on further details of the joint
venture in order to reach a final agreement by the end of April 2017.
5. Effects on Mitsubishi Tanabe Pharma's Performance
We will inform you of any potential effects on Mitsubishi Tanabe Pharma's futureperformance.
For further details, contact:
Public Relations Section,

Tel: +81-6-6877-4802

The Research Foundation for Microbial
Diseases of Osaka University
Corporate Communications Dept.,

Tel: +81-6-6205-5211

Mitsubishi Tanabe Pharma Corporation3